Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Pipeline Review, H1 2016

  • ID: 3743756
  • Report
  • 52 pages
  • Global Markets Direct
1 of 6
Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Pipeline Review, H1 2016

Summary

‘Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Pipeline Review, H1 2016’, provides in depth analysis on Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1)
- The report reviews Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6
List of Tables

List of Figures

Introduction

Report Coverage

Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) Overview

Therapeutics Development

Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Products under Development by Stage of Development

Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Products under Development by Therapy Area

Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Products under Development by Indication

Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Products under Development by Companies

Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Companies Involved in Therapeutics Development

Baxalta Incorporated

Kyorin Pharmaceutical Co., Ltd.

Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Drug Profiles

BaxB-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BaxG-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BaxM-159 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibudilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imalumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-88 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MIF-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-425 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Macrophage Migration Inhibitory Factor for Type 1 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Dormant Projects

Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) - Featured News & Press Releases

Apr 20, 2016: MediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada

Mar 30, 2016: MediciNova Announces Publication of Positive Findings from Completed Phase 1b Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence

Mar 22, 2016: FDA Grants Fast Track Designation for MediciNovas MN-166 (ibudilast) for Progressive Multiple Sclerosis

Mar 07, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis

Mar 06, 2016: MediciNova Announces Positive Findings From a Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry: Translational Research in Addiction Meeting in San Antonio, Texas

Feb 22, 2016: MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Dual Presentation at the American Academy of Neurology 68th Annual Meeting in Vancouver, Canada

Feb 11, 2016: MediciNova Announces Presentation Regarding MN-166 (ibudilast) and Methamphetamine Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas

Feb 07, 2016: MediciNova Announces Presentation of Data From the Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas

Jan 18, 2016: FDA Grants Rare Pediatric Disease Designation to MediciNova’s MN-166 (ibudilast) for the Treatment of Krabbe Disease

Dec 16, 2015: FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Baxalta Incorporated, H1 2016

Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
According to our recently published report 'Macrophage Migration Inhibitory Factor – Pipeline Review, H1 2016'; Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.

Furthermore, the publisher says; Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) Macrophage migration inhibitory factor (MIF) also known as glycosylation-inhibiting factor (GIF) is a protein that is encoded by the MIF gene. Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine produced by the pituitary gland and multiple cell types, including macrophages, dendritic cells (DC) and T-cells. Upon releases MIF modulates the expression of several inflammatory molecules, such as TNF-a, nitric oxide and cyclooxygenase 2 (COX-2). MIF is an important regulator of innate immunity. Antigens stimulate white blood cells to release MIF into the blood stream. The circulating MIF binds to CD74 on other immune cells and trigger an acute immune response. MIF plays a role in the regulation of macrophage function in host defense through the suppression of anti-inflammatory effects of glucocorticoid.

The report 'Macrophage Migration Inhibitory Factor – Pipeline Review, H1 2016' outlays comprehensive information on the Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor or L-Dopachrome Isomerase or MIF or EC 5.3.2.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 5 and 2 respectively.
Note: Product cover images may vary from those shown
5 of 6
Baxalta Incorporated
Kyorin Pharmaceutical Co., Ltd.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll